(207 days)
The evidence®Cannabinoids test has been designed for use only on the evidence® analyser to detect cannabinoids in urine, using a cut-off of 50ng/ml. Qualitative results obtained can be utilised in the diagnosis of cannabinoid use or abuse.
This assay provides only a preliminary analytical test result which should be confirmed by a more specific method, such as GC/MS.
The Cannabinoids Assay must only be used by suitably qualified laboratory personnel under appropriate laboratory conditions.
The evidence® Drugs of Abuse Calibrators.
The evidence®Drugs of Abuse Calibrators are liquid Calibrators containing benzoylecgonine, amphetamine, methamphetamine, methadone and 11-nor-D9-THC-9 carboxylic acid.
There are 9 levels of calibrator. They have been developed for use in calibration of the evidence® system.
The evidence®Drugs of Abuse Calibrators must only be used by suitably qualified laboratory personnel under appropriate laboratory conditions.
Not Found
This appears to be a 510(k) premarket notification letter for the Randox Laboratories, Ltd. "evidence® Cannabinoids Assay and evidence® Drugs of Abuse Calibrators." This type of document from the FDA primarily focuses on establishing substantial equivalence to a legally marketed predicate device, rather than a detailed study report demonstrating performance against specific acceptance criteria in the manner of a clinical trial for a novel AI/software medical device.
Therefore, the information requested in your prompt regarding acceptance criteria, study details, sample sizes, expert ground truth, MRMC studies, standalone performance, and training set information is not typically found in this kind of 510(k) letter. This letter is a regulatory approval document, not a scientific publication of a performance study.
To answer your request, I would need a different type of document, such as a summary of safety and effectiveness data (SSED) or a clinical study report that would accompany a premarket submission (PMA or a more detailed 510(k) for a device with novel characteristics).
Based on the provided document, I can infer the following limited information, but I cannot provide the detailed breakdown requested:
- Device Type: This is a diagnostic test kit (Cannabinoids Assay) and associated calibrators. It is not an AI/software medical device that performs image analysis or requires expert interpretation in the way your prompt implies.
- Performance (Inferential): The FDA determined the device is "substantially equivalent" to legally marketed predicate devices. This means its performance is considered comparable to existing devices already on the market. However, the specific performance metrics and acceptance criteria for this device are not detailed here. The indication for use mentions a "cut-off of 50ng/ml," which is a performance characteristic, but not a full set of acceptance criteria.
- Ground Truth (Inferential): The document states, "This assay provides only a preliminary analytical test result which should be confirmed by a more specific method, such as GC/MS." This implies that Gas Chromatography-Mass Spectrometry (GC/MS) is considered the "gold standard" or ground truth for confirming cannabinoid use, but this relates to post-assay confirmation, not how the ground truth for validating the assay itself was established during its development.
- No Information Available: All other specific details requested (sample sizes for test/training sets, data provenance, number/qualifications of experts, adjudication methods, MRMC studies, standalone performance, training set ground truth establishment) are not present in this FDA 510(k) letter.
In summary, I cannot fill out the requested table or provide the detailed study information because the provided document is a regulatory approval letter, not a performance study report for the device.
{0}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle or bird-like symbol with flowing lines, representing movement or progress. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the symbol. The logo is simple and monochromatic.
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
NOV ຂໍ້ 3ໍ້ 2004
Dr. Pauline Armstrong Regulatory Affairs Randox Laboratories, Ltd. 55 Diamond Road Crumlin, Co. Antrim United Kingdom BT29 4QY
Re: K041142
Trade/Device Name: evidence® Cannabinoids Assay and evidence® Drugs of Abuse Calibrators Regulation Number: 21 CFR 862.3870 Regulation Name: Cannabinoid test system Regulatory Class: Class II Product Code: LDJ, DKB Dated: October 26, 2004 Received: October 28, 2004
Dear Dr. Armstrong:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
{1}------------------------------------------------
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Sincerely yours,
Cornelia B. Lohs
Cornelia B. Rooks, MA Acting Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known):_
| Device Name: | evidence® CANNABINOIDS ASSAY ANDevidence® DRUGS OF ABUSE CALIBRATORS |
|---|---|
| -------------- | -------------------------------------------------------------------------- |
Indications For Use:
The evidence®Cannabinoids test has been designed for use only on the evidence® analyser to detect cannabinoids in urine, using a cut-off of 50ng/ml. Qualitative results obtained can be utilised in the diagnosis of cannabinoid use or abuse.
This assay provides only a preliminary analytical test result which should be confirmed by a more specific method, such as GC/MS.
The Cannabinoids Assay must only be used by suitably qualified laboratory personnel under appropriate laboratory conditions.
The evidence® Drugs of Abuse Calibrators.
The evidence®Drugs of Abuse Calibrators are liquid Calibrators containing benzoylecgonine, amphetamine, methamphetamine, methadone and 11-nor-D9-THC-9 carboxylic acid.
There are 9 levels of calibrator. They have been developed for use in calibration of the evidence® system.
The evidence®Drugs of Abuse Calibrators must only be used by suitably qualified laboratory personnel under appropriate laboratory conditions.
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
CDRH. Office of In Vitro Diagnostic Devices (OIVD) Concurre
Albert
Division Sign Off
Page 1 of
Office of In Vitro Diagne
510(k) K041192
§ 862.3870 Cannabinoid test system.
(a)
Identification. A cannabinoid test system is a device intended to measure any of the cannabinoids, hallucinogenic compounds endogenous to marihuana, in serum, plasma, saliva, and urine. Cannabinoid compounds includedelta -9-tetrahydrocannabinol, cannabidiol, cannabinol, and cannabichromene. Measurements obtained by this device are used in the diagnosis and treatment of cannabinoid use or abuse and in monitoring levels of cannabinoids during clinical investigational use.(b)
Classification. Class II (special controls). A cannabinoid test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).